PR

2024730

PR Heartseed Announces Positive Recommendation from Safety Monitoring Committee for Dose Escalation in Phase 1/2 Clinical Trial Dosed With HS-001

2024730

PR Notice of Listing on the Growth Market of the Tokyo Stock Exchange

2024626

PR Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange

202452

PR Heartseed.'s CFO, Mutsuki Takano, Named "Most Innovative CFO from Asia to Watch in 2024" by CXO Magazine

202449

PR Prof. Massimiliano Gnecchi, Renowned Translational Cardiology Expert, Delivers Lecture at Heartseed.

2024325

PR Heartseed CEO Keiichi Fukuda Wins Japanese Society for Regenerative Medicine "Achievement Award"

202436

PR Heartseed CEO Keiichi Fukuda Delivers Keynote on Regenerative Medicine at aichung Veterans General Hospital in Taiwan

2023111

PR Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

2023911

PR Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

202395

PR Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

1 2 3